Journal article
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
Abstract
We conducted a post hoc analysis to assess the potential impact of GAP (gender, age, physiology) stage on the treatment effect of nintedanib in patients with idiopathic pulmonary fibrosis. Outcomes were compared in patients at GAP stage I versus II/III at baseline in the INPULSIS® trials. At baseline, 500 patients were at GAP stage I (nintedanib 304, placebo 196), 489 were at GAP stage II (nintedanib 296, placebo 193) and 71 were at GAP stage …
Authors
Ryerson CJ; Kolb M; Richeldi L; Lee J; Wachtlin D; Stowasser S; Poletti V
Journal
ERJ Open Research, Vol. 5, No. 2, pp. 00127–02018
Publisher
European Respiratory Society (ERS)
Publication Date
4 2019
DOI
10.1183/23120541.00127-2018
ISSN
2312-0541